Startseite>>Signaling Pathways>> Metabolism>> PDE>>HA 130

HA 130

Katalog-Nr.GC14697

HA 130 ist ein selektiver Autotaxin (ATX)-Inhibitor mit einem IC50 von 28 nM.

Products are for research use only. Not for human use. We do not sell to patients.

HA 130 Chemische Struktur

Cas No.: 1229652-21-4

Größe Preis Lagerbestand Menge
10mg
90,00 $
Ship Within 7 Days
50mg
270,00 $
Ship Within 7 Days

Tel:(909) 407-4943 Email: sales@glpbio.com

Kundenbewertungen

Basiert auf Kundenrezensionen.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

HA130 is a selective autotaxin (ATX) inhibitor with an IC50 of 28 nM.

HA130 completely blocks the ability of ATX to promote TEM (transendothelial migration). HA130 at 0.3 μM completely ablates the activity of ATX on TK1 uropod formation[1].

HA130 slows T cell migration across lymph node HEVs. HA130 decreases the "outside HEVs/inside HEVs" ratio by 3-4-fold compared to vehicle-treated animals vehicle[1].The s.c. administration of HA130 induces marked lymphocyte accumulation within the endothelial cell (EC) and sub-EC layers of HEVs in draining lymph nodes (LNs)[2].

References:
[1]. Zhang Y, et al. Autotaxin through lysophosphatidic acid stimulates polarization, motility, and transendothelial migration of naive T cells. J Immunol. 2012 Oct 15;189(8):3914-3924.
[2]. Bai Z, et al. Constitutive lymphocyte transmigration across the basal lamina of high endothelial venules is regulated by theautotaxin/lysophosphatidic acid axis. J Immunol. 2013 Mar 1;190(5):2036-2048.

Bewertungen

Review for HA 130

Average Rating: 5 ★★★★★ (Based on Reviews and 27 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for HA 130

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.